← Back to directory

Nicolas Magné

Researcher Next ID · RN-022165

Researcher · Medicine

Centre National de la Recherche Scientifique

Paris, Colombia

Not currently recruitingFunding unknown
Works count
463
Citation count
10,350
H-index
54
i10-index
184

Research interests

Medicine
Physics and Astronomy
Biochemistry, Genetics and Molecular Biology
Head and Neck Cancer Studies
Advanced Radiotherapy Techniques
Prostate Cancer Diagnosis and Treatment
Endometrial and Cervical Cancer Treatments
Breast Cancer Treatment Studies

Publications

  • Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

    ˜The œLancet. Gastroenterology & hepatology · 2023 · 10.1016/s2468-1253(22)00392-2

  • Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

    The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00367-1

  • Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

    The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30454-x

  • Radiation-induced bystander and abscopal effects: important lessons from preclinical models

    British Journal of Cancer · 2020 · 10.1038/s41416-020-0942-3

  • Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

    The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30327-2

  • Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

    The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30486-3

  • Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies

    Critical Reviews in Oncology/Hematology · 2018 · 10.1016/j.critrevonc.2018.09.004

  • Nanoparticles in radiation oncology: From bench-side to bedside

    Cancer Letters · 2016 · 10.1016/j.canlet.2016.03.011

  • Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

    European Journal of Cancer · 2016 · 10.1016/j.ejca.2016.03.067

  • Radiation-enhanced cell migration/invasion process: A review

    Critical Reviews in Oncology/Hematology · 2014 · 10.1016/j.critrevonc.2014.05.006

  • Targeting Head and Neck Cancer Stem Cells to Overcome Resistance to Photon and Carbon Ion Radiation

    Stem Cell Reviews and Reports · 2013 · 10.1007/s12015-013-9467-y

  • Targeting a cornerstone of radiation resistance: Cancer stem cell

    Cancer Letters · 2012 · 10.1016/j.canlet.2012.03.024

  • Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients

    Critical Reviews in Oncology/Hematology · 2010 · 10.1016/j.critrevonc.2010.08.004

  • Physics Contributions and Clinical Outcome With 3D-MRI–Based Pulsed-Dose-Rate Intracavitary Brachytherapy in Cervical Cancer Patients

    International Journal of Radiation Oncology*Biology*Physics · 2008 · 10.1016/j.ijrobp.2008.06.1912

  • Phyllodes Tumor of the Breast

    International Journal of Radiation Oncology*Biology*Physics · 2007 · 10.1016/j.ijrobp.2007.06.059

  • Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy

    Annals of Oncology · 2007 · 10.1093/annonc/mdm548

  • Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network

    Radiotherapy and Oncology · 2007 · 10.1016/j.radonc.2007.10.015

  • Radiation recall: A well recognized but neglected phenomenon

    Cancer Treatment Reviews · 2005 · 10.1016/j.ctrv.2005.07.008

  • Pharmacological background of EGFR targeting

    Annals of Oncology · 2004 · 10.1093/annonc/mdh257

  • Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses

    Journal of Clinical Oncology · 2002 · https://doi.org/10.1200/jco.2002.09.091

  • Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer

    British Journal of Cancer · 2002 · 10.1038/sj.bjc.6600103

  • Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

    British Journal of Cancer · 2002 · 10.1038/sj.bjc.6600299

  • Percutaneous cementoplasty for pelvic bone metastasis

    Supportive Care in Cancer · 2000 · 10.1007/s005200000138

Current projects

    No projects listed.